Skip to main content
. 2022 Feb 24;23(4):e53746. doi: 10.15252/embr.202153746

Figure EV3. Iron enhances mitochondrial function and prevents cancer‐induced myotube atrophy.

Figure EV3

  1. Profile of oxygen consumption rate OCR in C2C12 myotubes after 48 h treatment with ferric citrate (n = 6).
  2. Myotube diameter normalized to Day 0 values (n = 3).
  3. Fusion index of C2C12 myotubes treated with C26 CM and ferric citrate for 48 h (n = 7–8).
  4. Diameter of C2C12 myotubes treated with LLC CM and iron citrate for 48 h (n = 3).
  5. Diameter of C2C12 myotubes treated with Activin A (ActA) and ferric citrate for 48 h (n = 3).
  6. Diameter of TFR1‐silenced C2C12 myotubes after 24 h treatment with iron ionophore hinokitiol (HNK) (n = 3).
  7. Diameter of C2C12 myotubes treated with C26 CM and HNK for 48 h (n = 3).

Data information: For all data, n represents the number of biological replicates. Statistical significance was calculated by one‐way Anova with Bonferroni’s correction (A‐E). Data are mean ± SEM. ***P < 0.001 compared to control and ###P < 0.001 compared to conditioned medium, ActA, or esiTFR‐treated group.